The last 5 years have seen the emergence of efficacious peptide-based therapies for obesity treatment that target glucagon-like peptide-1 receptor (GLP-1R), either selectively or via co-activation with related receptors, such as the glucose-dependent insulinotropic polypeptide and/or glucagon receptors 1
Dexmedetomidine, a sedative, deserves special mention: Dex acts on 2-adrenergic receptors to reduce catecholamine release and has been repeatedly shown to attenuate inflammation and organ injury in surgical and ICU patients (132, 133)
This is the active form of the molecule, ready to go to work neutralizing toxins and protecting cells
Hybrid membrane-coated biomimetic nanoparticles (HM@BNPs): a multifunctional nanomaterial for biomedical applications
It also exhibits antioxidant and anti-inflammatory properties relevant to scalp health
To view a copy of this licence, visit About this article Cite this article Sasal, W.M., Gmiter, D